The Neurotechnology Industry 2008 Report, market report, cns market report, CNS investment report

The Neurotechnology Industry 2009 Report
Published May 12, 2009

Drugs, Devices and Diagnostics for the Brain and Nervous System:  Market Analysis and Strategic Investment Guide of the Global Neurological Disease and Psychiatric Illness Markets

Now in its fifth year, The Neurotechnology Industry 2009 Report is an expanded and updated 480 page report of brain and nervous system markets and treatments. It is the only publication to provide a unified market-based framework to help investors, companies and entrepreneurs easily identify opportunities, understand the competitive landscape, determine risks and understand the dynamics of rapidly changing CNS markets. 

The report includes comprehensive information on products in development globally for over 18 indications at 550 companies including Alzheimer's, addiction, ALS, anxiety, depressive disorders, epilepsy, migraine, mild cognitive impairment, Huntington's, multiple sclerosis, obesity, pain, Parkinson's, schizophrenia, age-related macular degeneration, sensory disorders, sleep disorders, and stroke.

Report Highlights

The Neurotechnology Industry 2009 Report provides a unified market-based framework to help executives, investors, and governments easily identify opportunities, understand the competitive landscape and visualize the dynamics of these rapidly growing markets.
Purchase PDF
$4500

Purchase Hard Copy and PDF
$4700

 
  • 550 profiles of public and private neurotech companies including drugs, devices and diagnostics
  • 12 most active neurotech venture capital firms profiled with investments by market segment and U.S. neurotech venture capital trends (1999-Q12009)
  • Neurotech IPOs (2004-Q12009), M&A (2004-Q12009), Partnering and Licensing deals (2005-Q12009) and public neurotech stock performance
  • 18 brain and nervous system illness markets analyzed including: addiction, Alzheimer's disease, ALS anxiety, attention disorders, depression, epilepsy, hearing loss, insomnia, mild cognitive impairment, migraine, multiple sclerosis, obesity, pain, Parkinson's disease, retinal disorders, schizophrenia and stroke
  • Analysis of biological basis, current treatment options, and emerging therapeutic strategies
  • Analysis of compounds, cell therapies and devices in clinical trials and abandoned by company, mechanism of action and stage of development for each indication
  • Global and US market size, worldwide revenues for each indication for 2008
  • Extensive discussion of specific technological, demographic, regulatory and intellectual property